About PDL BioPharma
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: PDLI
- CUSIP: 69329Y10
- Previous Close: $2.28
- 50 Day Moving Average: $2.27
- 200 Day Moving Average: $2.73
- 52-Week Range: $1.93 - $3.84
- Trailing P/E Ratio: 2.16
- Foreward P/E Ratio: 11.40
- P/E Growth: 0.30
- Market Cap: $377.43M
- Outstanding Shares: 165,540,000
- Beta: 0.52
- Net Margins: 49.04%
- Return on Equity: 29.87%
- Return on Assets: 20.18%
Companies Related to PDL BioPharma:
- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 2.92%
- Quick Ratio: 2.91%
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How often does PDL BioPharma pay dividends? What is the dividend yield for PDL BioPharma?
PDL BioPharma announced a quarterly dividend on Wednesday, May 4th. Shareholders of record on Monday, June 6th will be given a dividend of $0.05 per share on Monday, June 13th. This represents a $0.20 dividend on an annualized basis and a yield of 8.77%. The ex-dividend date of this dividend is Thursday, June 2nd.
Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?
3 brokers have issued 12 month target prices for PDL BioPharma's stock. Their forecasts range from $3.50 to $4.00. On average, they anticipate PDL BioPharma's stock price to reach $3.83 in the next year.
When will PDL BioPharma announce their earnings?
PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about PDL BioPharma stock?
Here are some recent quotes from research analysts about PDL BioPharma stock:
According to Zacks Investment Research, "PDL BioPharma is focused on acquiring and managing income-generating assets. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. The latest example is that of privately held specialty pharmaceutical company, Noden Pharma. The ARIAD deal is another positive. We note that the company derives revenues primarily from royalties, which is not a risk-free strategy. Uncertainty related to the future source of revenues is another cause of concern. The company’s top line has declined materially after it stopped receiving payments from certain Queen et al. patent licenses. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year. Estimates are down ahead the company’s Q4 release." (1/17/2017)
Cowen and Company analysts commented, "PDL reported Q4 revenue of $178.1MM ahead of consensus of $167.9MME and GAAP." (2/23/2016)
Who owns PDL BioPharma stock?
PDL BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.78%), Dimensional Fund Advisors LP (2.59%), State Street Corp (2.58%), AQR Capital Management LLC (2.25%), Russell Investments Group Ltd. (1.17%) and GSA Capital Partners LLP (0.96%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke.
Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?
PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Guggenheim Capital LLC, Bowling Portfolio Management LLC, Zebra Capital Management LLC and Barrow Hanley Mewhinney & Strauss LLC.
Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?
PDL BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, AQR Capital Management LLC, Dimensional Fund Advisors LP, Allianz Asset Management AG, State Street Corp, Cigna Investments Inc. New and Federated Investors Inc. PA. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke.
How do I buy PDL BioPharma stock?
Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PDL BioPharma stock cost?
One share of PDL BioPharma stock can currently be purchased for approximately $2.28.